Biosimilar Hormones Global Market Report 2021: COVID-19 Growth And Change To 2030

·3 min read

Major players in the biosimilar hormones market are Teva Pharmaceutical, Gedeon Richter, Intas Pharmaceuticals, Biocon, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, and GC Pharma.

New York, Sept. 27, 2021 (GLOBE NEWSWIRE) -- announces the release of the report "Biosimilar Hormones Global Market Report 2021: COVID-19 Growth And Change To 2030" -

The global biosimilar hormones market is expected to grow from $1.94 billion in 2020 to $2.19 billion in 2021 at a compound annual growth rate (CAGR) of 12.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.35 billion in 2025 at a CAGR of 25%.

The biosimilar hormones market consists of sales of biosimilar hormones by entities that engage in manufacturing biosimilar hormones.These hormones are used when patients have a drop in hormones in their bodies or are unbalanced.

Only goods and services traded between entities or sold to end consumers are included.

The biosimilar hormones market covered in this report is segmented by type into teriparatide biosimilars, follitropin alfa biosimilars, insulin biosimilars, somatropin biosimilars, others and by application into research & biotechnology, diagnostics, biocatalysts, therapeutics, others.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Stringent regulations imposed on the approval of hormone biosimilars limits the growth of the biosimilar hormones market.Biosimilars are approved on the same standard of pharmaceutical quality, efficacy, and safety that apply to all biologics approved in the European Union.

There should be a similarity between the biologics and biosimilars, and as the process of manufacturing differs, the approval process becomes expensive and likely hinders the growth of the biosimilar hormones market.

In March 2018, BRAIN AG, a technology company in the field of industrial biotechnology, developing microorganisms, natural substances and enzymes for industrial use, acquired Biocatalysts for an undisclosed amount.The strategic acquisition of a majority stake in Biocatalysts is intended to accelerate product-driven growth in the fast-growing specialty enzyme market and broaden the portfolio of the enzyme business of BRAIN.

Biocatalysts is a US-based biotechnology company focused on the development, production and distribution of specialty enzymes for various industries such as food and fine chemicals.

The prevalence of deficiencies in growth hormones and metabolic hormones contributes to the market.The treatments required for hormone-related conditions are evolving over the years and the prevalence of hormonal deficiencies is generating higher demand for the hormone biosimilars market.

For instance, according to the Italian Journal of Pediatrics, the prevalence of growth hormone deficiency (GHD) in childhood widely varies between 1 out of 3480 and 1 out of 30,000 children annually.In children, the growth hormone can influence bone mineralization and lead to several metabolic effects, including glucose and lipid homeostasis.

Annually, about 6,000 adults are diagnosed with growth hormone (GH) deficiency in the USA. The growing need to treat patients with prevailing hormonal deficiencies drives the biosimilar hormones market.

Key players operating in the biosimilar hormones market are undertaking various strategic initiatives such as new product launch in untapped regions to make the drug accessible to a large population.The companies are focusing on launching their products across various locations to boost sales and maximize profits.

For instance, in October 2019, Biocon Biologics and Mylan N.V. announced the launch of biosimilar hormones in Australia to treat the polygenic disorder.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: US: (339)-368-6001 Intl: +1 339-368-6001

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting